Pharmacokinetics and safety of CXA-101, a new antipseudomonal cephalosporin, in healthy adult male and female subjects receiving single- and multiple-dose intravenous infusions.
about
Critical evaluation of ceftolozane-tazobactam for complicated urinary tract and intra-abdominal infectionsCeftolozane/tazobactam: a novel antipseudomonal cephalosporin and β-lactamase-inhibitor combinationProfile of ceftolozane/tazobactam and its potential in the treatment of complicated intra-abdominal infectionsAntimicrobial activity of CXA-101, a novel cephalosporin tested in combination with tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis strains having various resistance phenotypesRelationship between ceftolozane-tazobactam exposure and selection for Pseudomonas aeruginosa resistance in a hollow-fiber infection modelImpact of MIC range for Pseudomonas aeruginosa and Streptococcus pneumoniae on the ceftolozane in vivo pharmacokinetic/pharmacodynamic target.In vivo activities of ceftolozane, a new cephalosporin, with and without tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, including strains with extended-spectrum β-lactamases, in the thighs of neutropenic mice.Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli.Population pharmacokinetics of ceftolozane/tazobactam in healthy volunteers, subjects with varying degrees of renal function and patients with bacterial infections.Pharmacokinetics and safety of intravenous ceftolozane-tazobactam in healthy adult subjects following single and multiple ascending doses.Pan-β-lactam resistance development in Pseudomonas aeruginosa clinical strains: molecular mechanisms, penicillin-binding protein profiles, and binding affinities.Pharmacodynamics of Ceftolozane plus Tazobactam Studied in an In Vitro Pharmacokinetic Model of Infectionβ-Lactam Antibiotics Renaissance.Combinatorial Pharmacodynamics of Ceftolozane-Tazobactam against Genotypically Defined β-Lactamase-Producing Escherichia coli: Insights into the Pharmacokinetics/Pharmacodynamics of β-Lactam-β-Lactamase Inhibitor Combinations.Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. Hospitals (2011-2012).Population Pharmacokinetics and Safety of Ceftolozane-Tazobactam in Adult Cystic Fibrosis Patients Admitted with Acute Pulmonary Exacerbation.Will new antimicrobials overcome resistance among Gram-negatives?β-Lactam antimicrobials: what have you done for me lately?Ceftolozane/tazobactam (CXA 201) for the treatment of intra-abdominal infections.Ceftolozane/Tazobactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination.Ceftolozane/Tazobactam: A New Cephalosporin and β-Lactamase Inhibitor Combination.Ceftolozane/Tazobactam: A Review in Complicated Intra-Abdominal and Urinary Tract Infections.Efficacy, pharmacokinetic and pharmacodynamic profile of ceftolozane + tazobactam in the treatment of complicated urinary tract infections.Ceftolozane/tazobactam for the treatment of complicated urinary tract and intra-abdominal infections.Pharmacokinetics and Tissue Penetration of Ceftolozane/Tazobactam in Diabetic Patients with Lower Limb Infections and Healthy Adult Volunteers.In Vitro Activity of Ceftolozane-Tazobactam against Multidrug-Resistant Nonfermenting Gram-Negative Bacilli Isolated from Patients with Cystic Fibrosis.Efficacy of ceftolozane in a murine model of Pseudomonas aeruginosa acute pneumonia: in vivo antimicrobial activity and impact on host inflammatory response.Intrapulmonary penetration of ceftolozane/tazobactam and piperacillin/tazobactam in healthy adult subjects.Antibacterial activity of ceftolozane/tazobactam alone and in combination with other antimicrobial agents against MDR Pseudomonas aeruginosa.
P2860
Q26747429-7852C1B6-A8A5-4F76-A170-D228744B7471Q26998883-958B527E-DABF-451E-A296-51F3652257D3Q27001490-DF231F62-0741-4494-B939-FB9A033B502EQ34164594-EF519F53-FB8D-43F2-A8C7-DA7162F3E54EQ34298994-42B5C8F7-8CA8-4519-A2E4-A30C567C4EBAQ34299064-41365CF3-6A22-4E6A-8823-8B8958C18269Q34320027-A5F463FE-7673-4FFB-A755-919A927D8FEAQ34393008-04E4E1A7-F158-414B-B1E3-4DEC06EC3B78Q35004269-78C00528-44B0-45A0-8508-DFC703BA7F46Q36018548-E98296C3-F1D0-4903-8952-3005BB27A2CBQ36172484-3712452D-E037-4EAA-86F6-3FA5A8EB517CQ36438924-878F2818-AD41-482C-B021-41AD6FA8F9B9Q36683689-6D09E3CA-5AFA-4433-996B-96BECFE833C1Q36730017-5086AD0A-3572-4074-8A7C-E049A8094FBDQ37335781-3019062F-1DFA-4A6E-8771-02E8BA4CB691Q37358630-08DA09BF-1CF3-4D71-8CB3-CAD81FDECC05Q37942654-1A170246-BDF4-4CE0-BD1E-B48B88A4E0C6Q38076453-90A61FC1-DF87-4760-9A64-EC21ABAF35F6Q38241417-DB515167-53F6-49AE-86D6-B80BF3227F4CQ38541624-EDD9AB1B-B597-4B45-8894-B8C0A2A9E5C3Q38544744-D276201C-DAA5-4147-8963-3E48C94353F2Q38690748-25852A8F-6FB6-4FCD-87C9-3D92B3D8FDA9Q38872130-4BD2B8EA-7D16-44A0-B322-25C1BAC549ADQ39037981-713A31F6-4DB3-49A0-86EB-02CF2188BB2EQ40052714-E65E702D-8639-4110-89B1-CAD5E69E64E5Q41695599-64A14046-03B2-4EC9-B76B-A6ABCC679D52Q44053339-A06E3961-55F4-4506-83BB-6A83499531D8Q45289238-A686BBBB-F29B-43F6-B9DC-3FD8D55EBF5CQ49616791-CBF5C78B-9452-498A-8567-5FD84043BC47
P2860
Pharmacokinetics and safety of CXA-101, a new antipseudomonal cephalosporin, in healthy adult male and female subjects receiving single- and multiple-dose intravenous infusions.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Pharmacokinetics and safety of ...... le-dose intravenous infusions.
@ast
Pharmacokinetics and safety of ...... le-dose intravenous infusions.
@en
Pharmacokinetics and safety of ...... le-dose intravenous infusions.
@nl
type
label
Pharmacokinetics and safety of ...... le-dose intravenous infusions.
@ast
Pharmacokinetics and safety of ...... le-dose intravenous infusions.
@en
Pharmacokinetics and safety of ...... le-dose intravenous infusions.
@nl
prefLabel
Pharmacokinetics and safety of ...... le-dose intravenous infusions.
@ast
Pharmacokinetics and safety of ...... le-dose intravenous infusions.
@en
Pharmacokinetics and safety of ...... le-dose intravenous infusions.
@nl
P2093
P2860
P356
P1476
Pharmacokinetics and safety of ...... le-dose intravenous infusions.
@en
P2093
George H Talbot
Ian Friedland
M J Whitehouse
P2860
P304
P356
10.1128/AAC.01753-09
P407
P577
2010-05-10T00:00:00Z